Semaglutide vs Tirzepatide: One HPLC Method Fails Both

One RP-HPLC method and one 99% area-percent threshold cannot characterize both a semaglutide lot and a tirzepatide lot, because FDA's own review records treat their impurity profiles as structurally different testing problems. Buyers evaluating a joint quote should confirm that each compound's analytical file stands on its own, not on a single shared purity line.

The One-Certificate Assumption on a Two-SKU Order

The chemistry review supporting the oral semaglutide application, NDA 213051, describes release testing that pairs an RP-HPLC assay with peptide mapping for identity confirmation and with separate high molecular weight protein and sum-of-impurities testing. A separate document, the FDA's draft product-specific guidance for tirzepatide dated December 2025 and indexed as PSG_215866, sorts impurities into categories an area-percent figure cannot distinguish. Two federal documents, two different testing problems, one blanket purity statement pretending to cover both.^5,10

For a wholesale buyer the exposure is documentary rather than chemical. A shared method-suitability line means that if a downstream customer, an institutional purchaser, or an auditor asks which impurity class a given peak belongs to, the supplier has nothing to hand over but the same PDF that covered the other SKU. The question this article answers is narrow: what has to appear on paper, per compound, before a single-line purity statement can be treated as a characterization of the material at all.^5,10

What FDA's Oral Semaglutide Review Required at Release

The publicly posted chemistry review for application 213051 does not describe release as a chromatographic purity check with a pass number attached. It describes a panel. RP-HPLC assay appears alongside peptide mapping used for identity confirmation, and the impurity side of the panel is split into high molecular weight protein content and impurity plus sum-of-impurities determinations. Identity, assay, aggregate content and related substances are separate questions answered by separate tests, and the review record treats them that way.⁵

• RP-HPLC assay — the quantitative measurement most often reduced to a single area-percent line on a wholesale certificate.
• Peptide mapping — identity confirmation that does not rest on retention-time matching alone.
• High molecular weight protein (HMWP) — aggregate-class content reported independently of the assay.
• Impurities and sum of impurities — related substances reported individually and in aggregate.⁵

The documentary significance of the mapping requirement is easy to miss on a purchasing review. A chromatogram establishes that material eluted where the method expected material to elute, relative to a reference standard the buyer usually never sees. Peptide mapping is an orthogonal identity answer: it asks whether the fragment pattern of the substance in the vial matches the fragment pattern of the substance named on the label. A semaglutide purity specification that reports area percent and stops has answered how much of something, not what.⁵

What FDA's Draft Tirzepatide Guidance Puts in a Separate Class

The December 2025 draft product-specific guidance for tirzepatide, PSG_215866, organizes impurities along a line that no area-percent number crosses. Peptide-related process impurities are treated as their own category, and the draft guidance states that peptide-related impurities may affect the product's immunogenicity profile. Non-peptide process impurities are addressed separately and include particulate matter, residual solvents, and elemental impurities. Those are different analytical instruments, different sample preparations, and different sections of a release file.¹⁰

The third row is the one that changes a purchasing conversation. The draft guidance indicates that differences found in comparability studies assessing aggregates should be mitigated through changes in manufacturing strategy. That language points at process documentation, not at an analytical line item. A tirzepatide certificate of analysis that reports purity and nothing else is silent on all three categories the agency draft separates, and silent in three different ways.¹⁰

Why One RP-HPLC Run Cannot Cover Both Impurity Families

This is not an argument from first principles. Published stability-indicating RP-HPLC validation work states the limit plainly: no single currently available analytical method separates and quantifies all known related compounds, all degradation impurities, and unknown degradation products within a practical run time. Method development is a set of compromises — resolution against run time, sensitivity against selectivity — and every compromise is made with one molecule's impurity inventory in front of the analyst.²

The same literature reports the corollary that matters on a two-SKU purchase order: a method validated for one compound is frequently unsuitable for related-substance determination of another under ICH expectations. Suitability is a property of the pairing between method and molecule, not a property of the instrument. A statement that a laboratory runs a validated RP-HPLC related-substances method is therefore not a statement about either SKU until the validation is named against that SKU.²

• Column chemistry and dimensions, which fix which closely related peaks can be resolved.
• Gradient composition and duration, which fix total run time and late-eluting impurity recovery.
• Detection wavelength, which determines whether a given impurity is seen at all.
• The forced-degradation set used to demonstrate that the method is stability indicating.
• The relative retention time table that assigns identity to each reported peak.²

Map that against the two agency records. The semaglutide review pairs the chromatographic assay with an orthogonal identity method and with a separate aggregate measurement. The tirzepatide draft guidance splits impurities into peptide-related and non-peptide classes and hands aggregates to comparability and manufacturing strategy. A single chromatogram, however clean, answers the identity question for neither compound and the classification question for neither compound.^5,10

The Compound-Specific Validation Precedent from Other APIs

The documentation standard argued here is not novel to peptides. It is the ordinary standard in the published method-development record for small-molecule active ingredients, where each molecule received its own stress and forced-degradation study and its own impurity inventory before any method was declared stability indicating. A stability-indicating RP-UPLC method for rosuvastatin and its related substances was developed and validated for rosuvastatin, not adapted from a neighboring statin file and labeled suitable.⁶

Seven molecules, seven method files, no shared purity threshold standing in for any of them. Several of those papers went further and identified, characterized, or synthesized individual impurities so that a peak could be named rather than counted. Against that baseline, a peptide supplier offering one area-percent number for two structurally distinct GLP-1 analog materials is offering less documentation than the ordinary literature produces for a single tablet excipient system.^6,7,8

What a 99% Area-Percent Number Is Silent On

For a semaglutide lot, the gap is identity and aggregate content. Area percent reports the proportion of integrated signal falling under the main peak. It does not confirm the fragment pattern of the main peak, which is the function the 213051 review assigns to peptide mapping, and it does not report high molecular weight protein content, which that review lists as a separate determination. A lot can be 99.2% by area and undocumented on both counts.⁵

For a tirzepatide lot, the gap is classification. The residual 0.8% is a single number covering peaks the draft guidance would sort into a peptide-related class it associates with the immunogenicity profile and a non-peptide class comprising particulate matter, residual solvents, and elemental impurities — categories that the related-substances run does not measure. Aggregate comparability sits outside the certificate entirely, in manufacturing strategy records.¹⁰

• Which peak is the named substance, established by a method other than retention time.
• How the reported impurity total divides between peptide-related and non-peptide classes.
• Whether aggregate or high molecular weight content was measured, and by what method.
• Whether the method was shown to be stability indicating for that specific molecule.
• Which nomenclature, molecular formula and molecular weight the analyzing laboratory used to identify the reference standard.^5,10

Two Qualification Packages, Not One: Per SKU, Per Lot

The practical translation is a procurement rule rather than a chemistry preference. A quote covering both compounds should return two analytical files that share no sentences: one built against the semaglutide panel described in the 213051 review, one built against the impurity categories in PSG_215866. If the two files are the same file with the compound name swapped, the supplier has documented one material and asserted the other.^5,10

• The full chromatogram for the specific lot, with axes, gradient table, column, and wavelength legible — not a cropped image.
• A peak table listing relative retention times and the identity assigned to each reported peak.
• An identity result from a method independent of retention time, consistent with the peptide-mapping role in the 213051 review.
• An aggregate or high molecular weight result, reported as its own line rather than folded into total impurities.
• For tirzepatide, impurity reporting separated into peptide-related and non-peptide categories, with residual solvents and elemental impurities addressed by their own methods.
• The forced-degradation summary establishing that the related-substances method is stability indicating for that molecule.
• The storage condition and container closure under which the supporting stability data were generated, and the temperature excursion record on file for the shipped lot.^2,5,6,10

The forced-degradation summary is the cheapest diagnostic in that list. A laboratory that ran stress studies on the molecule can produce the stressed chromatograms in minutes, because they were generated once during method development and never change. A laboratory that inherited a generic related-substances method has nothing to send, and the published method-development record shows what that absence means: the impurity inventory the method is supposed to detect was never established for this compound.^2,6

Which Suppliers Stay Quotable, and How Each SKU Prices

Once the requirement is two packages, the supplier pool splits on capability rather than on price. A supplier who can produce the semaglutide panel in the form the 213051 review describes and the tirzepatide impurity categories the December 2025 draft guidance separates is holding two distinct analytical relationships and paying for two method validations. A supplier who cannot is quoting a document, and the document covers neither SKU to the standard an auditor will read.^5,10

Pricing follows the documentation, because the documentation is a real cost line. Two validated related-substances methods, two forced-degradation studies, aggregate testing, and non-peptide impurity work performed on separate instruments do not average out across SKUs. A quote that prices both compounds identically on the analytical side is usually a quote where the analytical work was done once.^2,10

• Request analytical documentation per SKU and per lot, and review the two files independently rather than as one packet.
• Treat identical method-suitability wording across two compounds as an open finding, not a formality.
• Hold acceptance of each SKU to its own document set, so a shortfall on one compound does not delay release of the other.
• Price the analytical package as a separate line from the material, so a supplier's testing cost is visible in the quote.

The argument reduces to one sentence a purchasing file can carry: semaglutide and tirzepatide are separate qualification problems in the agency's own records, and a supplier who merges them into one purity statement has produced a marketing line with a decimal point in it. Two files, or the SKU does not clear document review.^5,10